Form 4: PTC Therapeutics CEO Matthew Klein Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


CEO Matthew Klein sold shares of PTC Therapeutics stock to cover tax obligations related to the vesting of restricted stock units.

Summary

  • On February 19, 2025, Matthew B. Klein, CEO of PTC Therapeutics, sold 3,897 shares of common stock at a price of $50.096 per share.
  • On February 20, 2025, Klein sold an additional 3,895 shares of common stock at a price of $50.124 per share.
  • These sales were executed to cover tax withholding obligations associated with the vesting of 17,500 restricted stock units (RSUs) from a grant of 70,000 RSUs on February 15, 2025.
  • Following these transactions, Klein directly owns 276,038 shares of PTC Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations related to RSU vesting. It doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Executive stock sales are a common occurrence, particularly when tied to RSU vesting. It is important to consider the size of the sale relative to the executive's overall holdings and the company's performance when assessing the impact.

Stakeholder Impact

  • The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to have a significant long-term effect given the reason for the sale.

Key Dates

DateDescription
02/15/2025Grant of 70,000 RSUs
02/19/2025Sale of 3,897 shares of common stock
02/20/2025Sale of 3,895 shares of common stock
02/21/2025Date of signature on the Form 4 filing

Keywords

PTC Therapeutics, Matthew Klein, CEO, stock sale, Form 4, RSUs, tax obligations, insider trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.